DBV Technologies S.A. - American Depositary Shares (NQ:DBVT)

16.32 +0.71 (+4.55%)

Streaming Delayed Price Updated: 12:01 PM EDT, Jul 7, 2026 Add to My Watchlist

Price and Volume

Volume	104,105
Open	16.05
Bid (Size)	16.31 (100)
Ask (Size)	16.63 (100)
Prev. Close	15.61
Today's Range	15.78 - 16.41
52wk Range	8.510 - 26.18
Shares Outstanding	55,096,537
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

July 06, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing

June 29, 2026

From DBV Technologies S.A.

Via GlobeNewswire

Performance

YTD	-14.3%	-14.3%
1 Month	+2.0%	+2.0%
3 Month	-19.8%	-19.8%
6 Month	-3.9%	-3.9%
1 Year	+48.2%	+48.2%

More News

DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index

June 23, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference

June 09, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

June 08, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 05, 2026

From DBV Technologies S.A.

Via GlobeNewswire

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026

June 03, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies Announces the Results of its 2026 Combined General Meeting

June 03, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

June 02, 2026

From DBV Technologies S.A.

Via GlobeNewswire

Combined General Meeting of June 3, 2026

May 13, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

May 12, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies Reports First Quarter 2026 Financial Results

April 30, 2026

From DBV Technologies S.A.

Via GlobeNewswire

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

April 02, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

March 26, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies Reports Full Year 2025 Financial Results and Business Update

March 26, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

March 24, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies to Participate in Upcoming March Investor Conferences

March 04, 2026

From DBV Technologies S.A.

Via GlobeNewswire

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026

March 03, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

February 28, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

February 10, 2026

From DBV Technologies S.A.

Via GlobeNewswire

DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit

February 09, 2026

From DBV Technologies S.A.

Via GlobeNewswire

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

February 05, 2026

From DBV Technologies S.A.

Via GlobeNewswire

GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics

January 20, 2026

Via MarketMinute

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

January 16, 2026

From DBV Technologies S.A.

Via GlobeNewswire

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

January 12, 2026

From DBV Technologies S.A.

Via GlobeNewswire

Frequently Asked Questions

Is DBV Technologies S.A. - American Depositary Shares publicly traded?

Yes, DBV Technologies S.A. - American Depositary Shares is publicly traded.

What exchange does DBV Technologies S.A. - American Depositary Shares trade on?

DBV Technologies S.A. - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for DBV Technologies S.A. - American Depositary Shares?

The ticker symbol for DBV Technologies S.A. - American Depositary Shares is DBVT on the Nasdaq Stock Market

What is the current price of DBV Technologies S.A. - American Depositary Shares?

The current price of DBV Technologies S.A. - American Depositary Shares is 16.32

When was DBV Technologies S.A. - American Depositary Shares last traded?

The last trade of DBV Technologies S.A. - American Depositary Shares was at 07/07/26 12:01 PM ET

What is the market capitalization of DBV Technologies S.A. - American Depositary Shares?

The market capitalization of DBV Technologies S.A. - American Depositary Shares is 899.18M

How many shares of DBV Technologies S.A. - American Depositary Shares are outstanding?

DBV Technologies S.A. - American Depositary Shares has 899M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.